Novavax Inc’s (NVAX) stock was up 1.73% to trade at $125.6 in the premarket session today, despite the recent news that the company has again delayed the launch of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now plans it to launch next weak instead of November.
Although difficulties in gearing up the development of the vaccine have delayed the U.S. trial, Novavax has a late-stage study ongoing in the U.K. that concluded enrollment on Monday.
However, analysts have said that more than one vaccine will be needed to end the pandemic that has killed over 1.4 million people worldwide.
Duncan added that Novavax expects preliminary results from the U.K. trial in the first quarter of 2021 and may also seek global clearance in the United States and the United Kingdom following the initial data.
The business plans to use privately manufactured vaccine material for the trial in the United States and Mexico and has collaborated extensively with the United States.
In the first quarter of next year, the effectiveness evidence from that study will also be available.